Investing RAD 202 receives approval to start Phase 1 therapeutic trial December 20, 2024 Share Share on Facebook Share on Twitter Pinterest Email Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com 0 Prev Post Completion of Tranche 1 of the Placement December 20, 2024 Next Post PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis December 20, 2024 Related Posts Lode Gold Completes Final Tranche Financing for Total $1.51 Million August 9, 2025 Crypto Market Update: Ethereum Rallies Past US$4,000, Trump Orders Crypto Review in 401(k) August 9, 2025 OTCQB Venture Virtual Investor Conference: Presentations Now Available for Online Viewing August 9, 2025
Crypto Market Update: Ethereum Rallies Past US$4,000, Trump Orders Crypto Review in 401(k) August 9, 2025
OTCQB Venture Virtual Investor Conference: Presentations Now Available for Online Viewing August 9, 2025
